Open AccessAnticoagulant and antiplatelet combined therapy in patients 75 years and over with atrial fibrillation: a prospective observational study assessing adherence to clinical guidelines
Author(s) -
Anaïs Minary,
Bruno Michel,
B. Gourieux,
Thomas Vogel
Publication year - 2018
Publication title -
european journal of hospital pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.313
H-Index - 14
eISSN - 2047-9964
pISSN - 2047-9956
DOI - 10.1136/ejhpharm-2018-001520
Subject(s) - medicine , observational study , atrial fibrillation , antiplatelet drug , prospective cohort study , population , anticoagulant , hazard ratio , anticoagulant therapy , coronary artery disease , emergency medicine , surgery , aspirin , clopidogrel , confidence interval , environmental health
According to current guidelines on atrial fibrillation (AF), the addition of an antiplatelet therapy to an anticoagulant for a stable vascular disease does not decrease the ischaemic hazard but increases the risk of bleeding. The aim of the study was to assess compliance of practices with existing clinical guidelines concerning the use of anticoagulant-antiplatelet combined therapy in patients 75 years and over with AF.